Therapy and Toxicity of 3 novel antibody drug conjugates

This study will examine the therapeutic potential of a 3 novel antibody drug conjugates under development at Nordic Nanovector. These conjugates have not been tested previously in-vivo, and it is critical to their development that we understand their behavior inside a living animal bearing the human xenograft representative of the cancer they are designed to treat. By demonstrating the ADCs ability to delay tumor Growth compared with the proper controls, we can make a scientifically informed decision whether or not to move the candidates forward into human clincial trials for Lymphoma. We hypothesize that our ADCs will either delay growth compared to the controls or shrink tumor size after treatament. This study requires 417 mice total. In the intravenous arm of the therapy study, mice may become sick due to tumor cell inifltration in internal organs. the animal's health will be closely monitored and recorded in the attached Health score sheet, and euthenized should they reach any of the defined end points.